Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO ODT versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO ODT versus FOCALIN XR.
EVEKEO ODT vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant